49.38
price up icon0.26%   0.13
pre-market  Vorhandelsmarkt:  49.98   0.60   +1.22%
loading
Schlusskurs vom Vortag:
$49.25
Offen:
$48.8
24-Stunden-Volumen:
548.68K
Relative Volume:
0.75
Marktkapitalisierung:
$2.84B
Einnahmen:
$718.95M
Nettoeinkommen (Verlust:
$-38.55M
KGV:
-72.20
EPS:
-0.6839
Netto-Cashflow:
$45.99M
1W Leistung:
-2.83%
1M Leistung:
-7.35%
6M Leistung:
+4.84%
1J Leistung:
+51.01%
1-Tages-Spanne:
Value
$48.23
$49.87
1-Wochen-Bereich:
Value
$46.83
$50.48
52-Wochen-Spanne:
Value
$29.16
$59.68

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Name
Firmenname
Supernus Pharmaceuticals Inc
Name
Telefon
301-838-2500
Name
Adresse
9715 KEY WEST AVENUE, ROCKVILLE, MD
Name
Mitarbeiter
778
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
SUPN's Discussions on Twitter

Compare SUPN vs TAK, ZTS, HLN, TEVA, UTHR

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
SUPN icon
SUPN
Supernus Pharmaceuticals Inc
49.38 2.84B 718.95M -38.55M 45.99M -0.6839
TAK icon
TAK
Takeda Pharmaceutical Co Adr
18.04 56.99B 29.85B 776.90M 4.35B 0.2408
ZTS icon
ZTS
Zoetis Inc
115.93 48.94B 9.47B 2.67B 2.28B 6.0218
HLN icon
HLN
Haleon Plc Adr
9.70 43.30B 14.54B 2.22B 2.58B 0.4871
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
29.14 33.94B 17.41B 1.43B 1.00B 1.2182
UTHR icon
UTHR
United Therapeutics Corp
531.82 23.31B 3.18B 1.33B 1.04B 27.90

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-10-09 Hochstufung Piper Sandler Neutral → Overweight
2025-07-30 Hochstufung Cantor Fitzgerald Neutral → Overweight
2025-02-19 Herabstufung Cantor Fitzgerald Overweight → Neutral
2025-01-06 Eingeleitet Cantor Fitzgerald Overweight
2024-09-11 Herabstufung Piper Sandler Overweight → Neutral
2023-01-03 Fortgesetzt Jefferies Buy
2021-12-01 Fortgesetzt Jefferies Buy
2021-04-13 Hochstufung Jefferies Hold → Buy
2020-06-16 Hochstufung Piper Sandler Neutral → Overweight
2020-06-15 Fortgesetzt Jefferies Hold
2019-11-08 Herabstufung Berenberg Buy → Hold
2019-11-07 Herabstufung Stifel Buy → Hold
2019-11-06 Herabstufung Jefferies Buy → Hold
2018-11-12 Bestätigt B. Riley FBR Buy
2018-01-18 Bestätigt B. Riley FBR, Inc. Buy
2017-12-28 Bestätigt B. Riley FBR, Inc. Buy
2017-12-04 Hochstufung Janney Neutral → Buy
2017-11-08 Hochstufung Stifel Hold → Buy
2017-10-19 Eingeleitet FBR & Co. Buy
2017-09-19 Herabstufung Stifel Buy → Hold
2017-07-17 Herabstufung Piper Jaffray Overweight → Neutral
2017-07-14 Eingeleitet Janney Neutral
2017-06-01 Hochstufung Piper Jaffray Neutral → Overweight
2016-07-18 Herabstufung Northland Capital Outperform → Market Perform
2016-07-18 Herabstufung Piper Jaffray Overweight → Neutral
2016-02-08 Hochstufung Jefferies Hold → Buy
2015-11-05 Bestätigt Northland Capital Outperform
2015-10-28 Eingeleitet Northland Capital Outperform
Alle ansehen

Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten

pulisher
Mar 23, 2026

Jefferies reiterates Supernus Pharmaceuticals stock Buy rating By Investing.com - Investing.com South Africa

Mar 23, 2026
pulisher
Mar 23, 2026

Jefferies reiterates Supernus Pharmaceuticals stock Buy rating - Investing.com UK

Mar 23, 2026
pulisher
Mar 22, 2026

Breakout Watch: What is the target price for Supernus Pharmaceuticals Inc stockQuarterly Growth Report & Low Volatility Stock Suggestions - baoquankhu1.vn

Mar 22, 2026
pulisher
Mar 21, 2026

SUPN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Mar 21, 2026
pulisher
Mar 21, 2026

The Technical Signals Behind (SUPN) That Institutions Follow - Stock Traders Daily

Mar 21, 2026
pulisher
Mar 21, 2026

SUPN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Mar 21, 2026
pulisher
Mar 20, 2026

SUPN Technical Analysis & Stock Price Forecast - Intellectia AI

Mar 20, 2026
pulisher
Mar 18, 2026

Quarterly Risk: Does Supernus Pharmaceuticals Inc have strong EBITDA margins2026 Technicals & High Accuracy Buy Signal Tips - baoquankhu1.vn

Mar 18, 2026
pulisher
Mar 18, 2026

Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) VP Sells 7,250 Shares of Stock - MarketBeat

Mar 18, 2026
pulisher
Mar 18, 2026

Supernus Pharmaceuticals (NASDAQ:SUPN) VP Sells $2,514,000.00 in Stock - MarketBeat

Mar 18, 2026
pulisher
Mar 18, 2026

[Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

Supernus Pharmaceuticals Q4 2025 earnings preview - MSN

Mar 18, 2026
pulisher
Mar 17, 2026

SUPN (NASDAQ: SUPN) Form 144 lists 57,250-share resale after option exercise - Stock Titan

Mar 17, 2026
pulisher
Mar 17, 2026

SUPN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Mar 17, 2026
pulisher
Mar 17, 2026

Supernus Pharmaceuticals CEO Sells $1.76M in Stock - National Today

Mar 17, 2026
pulisher
Mar 16, 2026

Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - MSN

Mar 16, 2026
pulisher
Mar 16, 2026

Insider Sell Alert: Frederick Hudson Sells Shares of Supernus Ph - GuruFocus

Mar 16, 2026
pulisher
Mar 16, 2026

[144] SUPERNUS PHARMACEUTICALS, INC. SEC Filing - Stock Titan

Mar 16, 2026
pulisher
Mar 16, 2026

Supernus (NASDAQ: SUPN) CEO-linked KBT Trust sells 35,000 shares under 10b5-1 plan - Stock Titan

Mar 16, 2026
pulisher
Mar 16, 2026

Director at Supernus (NASDAQ: SUPN) sells 5,369 shares - Stock Titan

Mar 16, 2026
pulisher
Mar 16, 2026

SUPN SEC FilingsSupernus Pharma 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 16, 2026
pulisher
Mar 15, 2026

Assessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Mixed Short And Long Term Returns - simplywall.st

Mar 15, 2026
pulisher
Mar 15, 2026

Aristotle Capital Boston LLC Sells 503,122 Shares of Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat

Mar 15, 2026
pulisher
Mar 12, 2026

Insider sale of 5,369 shares at SUPN (NASDAQ: SUPN) - Stock Titan

Mar 12, 2026
pulisher
Mar 12, 2026

Supernus Pharmaceuticals Stock Review: Valuation & Business Quality ConcernsNews and Statistics - IndexBox

Mar 12, 2026
pulisher
Mar 12, 2026

3 Reasons SUPN is Risky and 1 Stock to Buy Instead - Yahoo Finance

Mar 12, 2026
pulisher
Mar 11, 2026

Supernus at Barclays Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com Canada

Mar 11, 2026
pulisher
Mar 11, 2026

To promote Zurzuvae, Biogen and Supernus are Turning Tides against postpartum depression - Medical Marketing and Media

Mar 11, 2026
pulisher
Mar 11, 2026

Supernus Pharmaceuticals, Inc. $SUPN Shares Acquired by Jefferies Financial Group Inc. - MarketBeat

Mar 11, 2026
pulisher
Mar 11, 2026

Dimensional Fund Advisors LP Lowers Holdings in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat

Mar 11, 2026
pulisher
Mar 10, 2026

Supernus (NASDAQ: SUPN) CEO exercises performance units, withholds shares for taxes - Stock Titan

Mar 10, 2026
pulisher
Mar 10, 2026

Supernus (SUPN) SVP Mottola sells shares after exercising 3,750 PSUs - Stock Titan

Mar 10, 2026
pulisher
Mar 10, 2026

SUPERNUS (NASDAQ: SUPN) CFO exercises performance units, settles taxes in shares - Stock Titan

Mar 10, 2026
pulisher
Mar 10, 2026

Supernus (NASDAQ: SUPN) SVP sells 8,877 shares after exercising 7,500 PSUs - Stock Titan

Mar 10, 2026
pulisher
Mar 10, 2026

[Form 3] SUPERNUS PHARMACEUTICALS, INC. Initial Statement of Beneficial Ownership - Stock Titan

Mar 10, 2026
pulisher
Mar 10, 2026

Precision Trading with Supernus Pharmaceuticals Inc. (SUPN) Risk Zones - Stock Traders Daily

Mar 10, 2026
pulisher
Mar 10, 2026

Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Victory Capital Management Inc. - MarketBeat

Mar 10, 2026
pulisher
Mar 10, 2026

Todd Horich sells 4,438 SUPN shares (NASDAQ: SUPN) in Form 144 filing - Stock Titan

Mar 10, 2026
pulisher
Mar 09, 2026

Insider Selling Alert: Georges Gemayel Sells Shares of Supernus Pharmaceuticals Inc (SUPN) - GuruFocus

Mar 09, 2026
pulisher
Mar 09, 2026

Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) Director Sells 10,000 Shares of Stock - MarketBeat

Mar 09, 2026
pulisher
Mar 09, 2026

Form 144: Proposed sale of 4,438 shares by SUPN insider (SUPN) - Stock Titan

Mar 09, 2026
pulisher
Mar 09, 2026

Director at Supernus (NASDAQ: SUPN) sells 18,787 shares of stock - Stock Titan

Mar 09, 2026
pulisher
Mar 09, 2026

American Century Companies Inc. Decreases Position in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat

Mar 09, 2026
pulisher
Mar 08, 2026

Recap Report: Is Supernus Pharmaceuticals Inc being accumulated by smart moneyTrade Analysis Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn

Mar 08, 2026
pulisher
Mar 08, 2026

Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Buy" at Wall Street Zen - MarketBeat

Mar 08, 2026
pulisher
Mar 07, 2026

Assessing Supernus Pharmaceuticals (SUPN) Valuation After Q4 Results And 2026 Guidance Update - Sahm

Mar 07, 2026
pulisher
Mar 06, 2026

B of A Securities Initiates Coverage of Supernus Pharmaceuticals (SUPN) with Buy Recommendation - MSN

Mar 06, 2026
pulisher
Mar 06, 2026

Georges Gemayel sells shares under Rule 144 (SUPN) - Stock Titan

Mar 06, 2026
pulisher
Mar 06, 2026

Citigroup Inc. Lowers Stake in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat

Mar 06, 2026
pulisher
Mar 05, 2026

GW&K Investment Management LLC Sells 184,268 Shares of Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat

Mar 05, 2026
pulisher
Mar 03, 2026

Supernus (NASDAQ: SUPN) CFO receives performance share unit grant - Stock Titan

Mar 03, 2026

Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
RDY RDY
$13.45
price down icon 1.75%
RGC RGC
$24.43
price down icon 3.13%
$24.90
price up icon 1.88%
$127.86
price up icon 0.64%
$13.36
price up icon 0.53%
$531.82
price up icon 2.03%
Kapitalisierung:     |  Volumen (24h):